Abstract
BackgroundUpadacitinib is a Janus kinase inhibitor under evaluation for the treatment of psoriatic arthritis (PsA). We evaluated upadacitinib in patients with PsA and prior inadequate response or intolerance to at...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have